



MARKET RELEASE

15 October 2009

Tissue Therapies Limited

TRADING HALT

The securities of Tissue Therapies Limited (the "Company") will be placed in pre-open at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in pre-open until the earlier of the commencement of normal trading on Monday, 19 October 2009 or when the announcement is released to the market.

Security Code: TIS

A handwritten signature in black ink, appearing to be 'R. Abeyewardene', is positioned above the name of the signatory.

Rohan Abeyewardene
Senior Adviser, Issuers (Brisbane)



TISSUE THERAPIES

ASX RELEASE

15 October 2009

Tissue Therapies requests voluntary trading halt

Tissue Therapies Limited (**Tissue Therapies**) has today voluntarily requested a trading halt of its securities immediately pending an announcement regarding a capital raising which is intended to be released to the market before commencement of trade on 19 October 2009.

The Company is not aware of any reason why its securities should not be suspended as requested.

Further information:

Dr Steven Mercer
CEO, Tissue Therapies Limited
Telephone: 07 3839 9938

Email: s.mercer@tissuetherapies.com

About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue and various cell culture applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a platform technology developed by tissue engineering experts at the Institute for Health and Biomedical Innovation at QUT for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, stem cell therapies and other cell culture uses.

Based on its VitroGro® platform technology, Tissue Therapies is developing more effective medical treatments for wounds and burns, integration of orthopaedic and medical implants, and other applications such as cosmeceuticals.

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: www.tissuetherapies.com